SEC Form 20-F filed by Concord Medical Services Holdings Limited
$CCM
Medical/Nursing Services
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
BEIJING, Dec. 2, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2025 annual general meeting of shareholders (the "Meeting") on December 29, 2025, at 10:00 a.m. (Beijing Time). The meeting will be held at Room 26A1-26A5, East Tower, Hanwei Building, No. 7 Guanghua Road, Chaoyang District, Beijing, China. The shareholder record date is December 19, 2025. A copy of the notice of Meeting is available on the Company's investor relations website at https://ir.ccm.cn. No proposal will be submitted
BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1]. 2025 First Half Highlights Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network
BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma. Choroidal malignant melanoma is a common intraocular malignancy. The traditional standard treatment is enucleation, i.e. eye removal. Although enucleation can effect
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1]. 2025 First Half Highlights Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network
BEIJING, Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2024[1]. 2024 First Half Highlights Total net revenues were RMB218.8 million (US$30.1 million) in the first half of 2024, representing a 23.1% decrease from total net revenues of RMB284.5 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB137.8 million (US$19.0 million) and the net revenues from the network
BEIJING, Sept. 22, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2023[1]. 2023 First Half Highlights Total net revenues were RMB284.5 million (US$39.2 million) in the first half of 2023, representing a 97.2% increase from total net revenues of RMB144.3 million in the same period last year. Total net rev
SC 13G/A - Concord Medical Services Holdings Ltd (0001472072) (Subject)
BEIJING, Dec. 28, 2020 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that the Company has, through its subsidiaries, entered into a definitive agreement to sell 90% equity interest in Concord Healthcare Singapore Pte Ltd, which operates and owns a general medical and surgical hospital, namely Concord International Hospital ("CIH"), for a total consideration of approximately SG$52.2 million. The p